Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Wu, Ju Gang ^a   Yu, Ji Wei ^a   Wu, Hong Biao ^a   Zheng, Lin Hai ^a   Ni, Xiao Chun ^a   Li, Xiao Qiang ^a   Du, Guang Ye ^a   Jiang, Bo Jian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

c MET; Cancer Neoplasm; E2f 1; Ki 67; Prognosis; Stomach

Indexed keywords

E2F1 PROTEIN, HUMAN; KI 67 ANTIGEN; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR E2F1; TUMOR PROTEIN;

ADENOCARCINOMA; AGED; ARTICLE; CANCER STAGING; CHEMISTRY; FEMALE; FOLLOW UP; GASTRECTOMY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN PROCESSING; STOMACH TUMOR;

ADENOCARCINOMA; AGED; E2F1 TRANSCRIPTION FACTOR; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 84891520247     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-6     Document Type: Article

References (26)

1. How is SOS activated? Let us count the ways. Findlay GM, Pawson T, Nat Struct Mol Biol 2008 15 538 540 10.1038/nsmb0608-538 18523461 (Pubitemid 351799144)
2. Regulation of ras signaling dynamics by Sos-mediated positive feedback. Boykevisch S, Zhao C, Sondermann H, Philippidou P, Halegoua S, Kuriyan J, Bar-Sagi D, Curr Biol 2006 16 2173 2179 10.1016/j.cub.2006.09.033 17084704 (Pubitemid 44767628)
3. Phosphorylation of pRb by cyclin D kinase is necessary for development of cardiac hypertrophy. Hinrichsen R, Hansen AH, Haunso S, Busk PK, Cell Prolif 2008 41 813 829 10.1111/j.1365-2184.2008.00549.x 18700867
4. The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T, Komine C, Yokoyama T, Fukushima T, J Neuropathol Exp Neurol 2005 64 398 403 15892297 (Pubitemid 40629130)
5. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, De Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazzini L, Volinia S, Alder H, Ruco LP, Baldassarre G, Croce CM, Vecchione A, Cancer Cell 2008 13 272 286 10.1016/j.ccr.2008.02.013 18328430 (Pubitemid 351318375)
6. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Christensen JG, Burrows J, Salgia R, Cancer Lett 2005 225 1 26 10.1016/j.canlet.2004.09.044 15922853 (Pubitemid 40732764)
7. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, Hölscher AH, Mönig SP, Oncol Rep 2008 19 1477 1483 18497953
8. Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma. Lee SW, Kang SB, Kim YS, Nam SW, Lee DS, Lee HK, Han SW, Korean J Gastroenterol 2007 49 152 157 18172343
9. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Tsamandas AC, Kardamakis D, Tsiamalos P, Liava A, Tzelepi V, Vassiliou V, Petsas T, Vagenas K, Zolota V, Scopa CD, Anticancer Res 2009 29 703 709 19331225
10. Perspectives in the treatment of gastric cancer. Roukos DH, Kappas AM, Nat Clin Pract Oncol 2005 2 98 107 10.1038/ncponc0099 16264882 (Pubitemid 40790143)
11. The treatment of advanced gastric cancer: current strategies and future perspectives. Cervantes A, Roselló S, Roda D, Rodríguez-Braun E, Ann Oncol 2008 19 Suppl 5 103 107
12. Japanese Classification of Gastric Carcinoma-2nd English Edition. Japanese Gastric Cancer Association, Gastric Cancer 1998 1 10 24 11957040
13. Influencing factors and clinical significance of the metastatic lymph nodes ratio in gastric adenocarcinoma. Yu JW, Wu JG, Zheng LH, Zhang B, Ni XC, Li XQ, Jiang BJ, J Exp Clin Cancer Res 2009 28 55 10.1186/1756-9966-28-55 19393100
14. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, Lee I, Sohn TS, Noh JH, Heo JS, Kim S, Lim Do H, Kim KM, Kang WK, Clin Cancer Res 2008 14 82 88 10.1158/1078-0432.CCR-07-0612 18172256 (Pubitemid 351409260)
15. Transcription factor E2F-1 is upregulated in human gastric cancer tissues and its overexpression suppresses gastric tumor cell proliferation. Xiao Q, Li L, Xie Y, Tan N, Wang C, Xu J, Xia K, Gardner K, Li QQ, Cell Oncol 2007 29 335 349 17641417 (Pubitemid 47037247)
16. Gastric Neoplasia. Mercer DW, Robinson EK, Sabiston Textbook of Surgery. The Biological Basis of Modern Surgical Practice Philadelphia, Pennsylvania: Elsevier Saunders, Townsend CMJr, Beauchamp RD, Evers BM, Mattox KL, 17 2004 1302 1312
17. Study on lymph node metastasis correlated to lymphangiogenesis, lymphatic vessel invasion and lymph node micrometastasis in gastric cancer. Yu JW, Wu JG, Tajima Y, Li XQ, Du GY, Zheng LH, Zhang B, Ni XC, Jiang BJ, J Surg Res 2011 168 188 196 10.1016/j.jss.2009.10.030 20189585
18. Interaction of the pRB-family proteins with factors containing paired-like homeodomains. Wiggan O, Taniguchi-Sidle A, Hamel PA, Oncogene 1998 16 227 236 10.1038/sj.onc.1201534 9464541 (Pubitemid 28045109)
19. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Li Y, Guessous F, DiPierro C, Zhang Y, Mudrick T, Fuller L, Johnson E, Marcinkiewicz L, Engelhardt M, Kefas B, Schiff D, Kim J, Abounader R, Mol Cancer Ther 2009 8 376 385 10.1158/1535-7163.MCT-08-0627 19190120
20. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y, Culliford AT 4th, D'Alessio M, Barany F, Paty PB, Cancer Lett 2008 265 258 269 10.1016/j.canlet.2008.02.049 18395971
21. The E2F family and the role of E2F1 in apoptosis. Wu Z, Zheng S, Yu Q, Int J Biochem Cell Biol 2009 41 2389 2397 10.1016/j.biocel.2009.06.004 19539777
22. Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Schayek H, Bentov I, Rotem I, Pasmanik-Chor M, Ginsberg D, Plymate SR, Werner H, Growth Horm IGF Res 2010 20 68 72 10.1016/j.ghir.2009.08.001 19703789
23. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, Wada H, Clin Cancer Res 2007 13 6938 6946 10.1158/1078-0432.CCR-07-1539 18056168 (Pubitemid 350276873)
24. The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage. Cassimere EK, Pyndiah S, Sakamuro D, Cell Death Differ 2009 16 1641 1653 10.1038/cdd.2009.98 19629135
25. The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1. Jenal M, Trinh E, Britschgi C, Britschgi A, Roh V, Vorburger SA, Tobler A, Leprince D, Fey MF, Helin K, Tschan MP, Mol Cancer Res 2009 7 916 922 10.1158/1541-7786.MCR-08-0359 19491197
26. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Dong YB, Yang HL, Elliott MJ, McMasters KM, Cancer Res 2002 62 1776 1783 11912154 (Pubitemid 34408502)